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NATURAL KIL LER LYMPHOCYTE MEMBRANE ANTIGENS INVOLVED IN
ALLORECOGNITION TARGETING. Kevin E. Bishoff, Jeffrey R. Bender.
Section of Cardiovascular Medicine, Department of Internal Medicine,
and the Molecular Cardiobiology Program, Boyer Center for Molecular
Medicine, Yale University, School of Medicine, New Haven, CT.
It has been recently established that natural killer (NK)
lymphocytes have alloantigen recognition capabilities, although the
membrane receptor(s) involved is unknown.

In the current study, I

attempt to characterize such receptors, utilizing an immortal B cell
line (RPMI8866) which drives the clonal expansion of antigenspecific NK cells.

My hypothesis is that NK cells have a receptor

structure that enables them to recognize and specifically lyse these
targets.
Murine monoclonal antibodies (mAbs) specific for NK cells were
generated and screened by flow cytometry for NK cell specificity and
effect on NK cell function.

Utilizing RPMI8866-stimulated NK cells as

effectors, 2 mAbs (1F7 and 1F8) were defined which partially inhibit
lysis (54% and 36% inhibition, respectively, at a 33:1 effector to
target ratio) of the stimulating RPMI8866 cell line but not the
classical NK-sensitive target K562 at any effector to target ratio.
These results support the hypothesis that NK cells have surface
receptors involved in specific target recognition and describe two
mAbs which appear to recognize such structures.
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1
INTRODUCTION
Natural killer (NK) cells are a bone marrow derived subset of
lymphocytes found in blood and lymphoid tissues (1).

NK cells

comprise 1% to 25% of cells in the peripheral blood of humans (2).
Because they appear morphologically as large cells with numerous
cytoplasmic granules, NK cells are also called large granular
lymphocytes (LGLs) in the literature.

In a manner analogous to

cytotoxic T lymphocytes (CTLs), NK cells kill their targets by granule
exocytosis and secretion of a cell toxin.

However, unlike CTLs, NK

cells do not require prior contact with target antigens to develop
cytolytic capacities or cytokine responsiveness (1).

The name

'natural killer' refers to this ability to lyse certain cells without prior
sensitization or restriction by major histocompatibility complex
(MHC) class I or II gene products (2-4).

That is, they mediate

cytolytic reactions that do not require expression of class I or class II
MHC molecules on the target cells (3).
Although there is a subset of T cells which can also lyse their
targets in an MHC-unrestricted fashion, NK cells are distinct from this
subset in that they lack the surface molecule CD3 and the T cell
receptor (TCR) for antigen recognition.

Unlike B and T cells,

respectively, NK cells do not undergo Ig or TCR rearrangement,
which, via the creation of a variety of surface receptors, enables
them to specifically recognize antigens.

Lymphocytes without slg or

TCR perform "nonspecific" lethal action on various susceptible cell
types but, in general, were previously considered unable to recognize
antigen(s).
From its discovery in 1974 until very recently, identification of
the NK cell based solely on its morphologic characteristics, and on
certain of its known functions, some which are shared with other cell
types, such as monocytes, macrophages and activated T cells, posed a
major limitation to NK cell analysis.

Monoclonal antibodies (mAbs) to

cell surface molecules can phenotype NK cells, differentiating them
from other lymphoid cells with common cytotoxic activity or
morphology.

Surface antigens expressed on human NK cells include

class I, CD2, CD7, CD8, CDlla, b, c/CD18 (LFA-1, Mac-1, pl50,95),
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CD16 (the NK cell Fc receptor for IgG), CD56, and CD57 (5).

Although

none of these antigens is unique to NK cells, the combination of CD 16
and CD56 on a cell lacking the T cell-associated CD3 molecule, is
thought to be definitive of the NK cell.
The clinical relevance of the NK cell is still a matter of debate
as its function and purpose in normal immunity is not completely
understood.

Given the lag period between exposure to foreign

materials and the development of specific immunity, NK cells were
initially thought to be a part of a primary broader-range defense
system that can act almost immediately until specific immunity
develops (4).

However, from in vitro experiments, it has been

inferred that NK cells produce lymphokines including interleukin 2
(IL-2) and interferon alpha, and serve in a regulatory capacity to the
adaptive immune system and to hematopoiesis, in addition to
confering 'natural' resistance against tumors, microbes, fungal, and
parasitic agents (6,7).

Moreover, it is not known whether all these

functions can be mediated by the same cells or whether distinct
functional subsets within the NK cell population have different
activities (7).

Since NK cells have been shown to secrete a variety of

lymphokines, it is also not known which of these functions is
mediated by direct cytotoxicity and which is mediated through
lymphokine secretion (7).
NK cells are able to kill virally infected cells and malignant
transformed cells in vitro, however they have not been found in
inflammatory infiltrates associated with viral infection or tumor (1).
The great potential of clinical benefit from understanding NK cell
function stems from the wide range of possible targets of NK cell
killing, and perhaps that there exist functions beyond cytolysis,
including target cell activation and amplification of immune
responses.
Early work with NK cells completed in animals revealed their
significance in the immune surveillance against the establishment of
primary tumors, as well as in controlling the spread of distant
metastases (8).

IL-2 in vivo and in vitro enhance NK cell cytolytic

activity, enabling them to lyse tumor-cell targets that are resistant to
unstimulated NK cells (8).

Not only the range of tumor cell
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recognition, but also the intensity of killing, was shown to highly
increase after culture of NK cells in IL-2 containing media (9).

In

addition, NK cells can be induced to proliferate by high
concentrations of IL-2 (1).

The effectiveness of these lymphokine-

activated killer (LAK) cells has been evaluated in a series of clinical
trials in which patients received recombinant IL-2
conjunction with LAK cells generated in vitro.

alone or in

The metastatic

tumors, most often metastatic renal-cell carcinoma or melanoma,
regressed in some of the patients who were treated with LAK cells or
IL-2 (8).
A number of studies in animals have identified a potentially
important role for NK cells in the immune response to certain viral
infections (8).

In these experiments, NK cells responded rapidly to a

viral challenge and mounted both a proliferative and a cytolytic
response 4-6 days before a T cell response could be mobilized.
is a little evidence of such a role in humans.

There

Partial deficiencies of

NK cells have been documented in a variety of clinical circumstances,
including

Chediak-Higashi

syndrome,

leukocyte-adhesion-molecule

(CD11/CD18) deficiency, X-linked lymphoproliferative disorder (XLPD), and the chronic fatigue syndrome.

Unlike patients with X-LPD,

in whom the NK cell defect is subsequent to EBV infection and might
be induced by the virus, the NK cell-deficient patients had a history
of repeated viral infection before EBV (6).
In the few patients who have a selective absolute deficiency of
NK cells, there is a prevalence of viral pathology.

Biron et ai

described one 17-year-old woman with a total deficiency of NK cells,
but normal T and B cell function, who had life-threatening infections
with three common herpesviruses:
herpes simplex virus (8).

varicella, cytomegalovirus, and

Eventually specific T and B cell responses

could be mobilized, but only after the one to two week time period
required for recognition and amplification of these responses.

From

these data, it appears that NK cells, together with interferon and
other natural resistance mechanisms, represent the first line of
defense against infection by certain viruses.
Their most impressive, and histologically supported, clinical
function may be in the initiation of graft-versus-host disease (GVHD)
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in the recipients of allotransplants.

Postulated as central to the

phenomenon of allograft rejection are the interactions between
lymphocytes and microvascular EC, the initial allogenic barrier with
which circulating host lymphocytes contact donor tissue in
vascularized allografts (10).

NK cells bind avidly to (10), induce the

appearance of class II MHC antigens on (11), and promote striking
morphologic alterations in microvascular EC (12) in vitro.
membrane protein lymphocyte

function-associated

Integral

antigen-1

(LFA-

1) plays a major role in lymphocyte binding to microvascular EC (10),
and consequently, induction of EC surface class II expression (11),
which is viewed as a sign and a major stimulus of the rejection
process (10).

The surface density of LFA-1 on NK cells is

approximately five times greater than that on CD4+ cells (13).
In vivo

data obtained mainly in the mouse suggests that NK

cells are involved in the rejection of bone marrow transplants (14).
NK cells are the effectors of the genetically restricted hybrid
resistance to parental grafts (12).

In humans Lopez et al. found an

association between high pretransplantation NK cell activity in the
recipient against HSV-1 infected target cells and incidence of GVHD
after bone marrow transplantation (6).

LGLs have been found in

fine-needle aspirates from kidney transplant patients in the
beginning and early stages of rejection, where their corresponding
peripheral blood levels were much lower (15).

However, the

expression of CD 16 and CD56 on these LGLs was not reported.
NK cells are found inside rat renal allografts during rejection.
They appear, with strong cytotoxic activity, and disappear in situ,
prior to the arrival of cytotoxic T lymphocytes (14).

From these data,

the authors hypothesized that NK cells may have a role in the
maturation of the CTL, possibly acting as primary cells for CTL.
Furthermore, the presence of NK cells in the renal allograft was
simultaneous with their depletion from the spleen, suggesting that
they are spleen-derived and not synthesized in situ.

However, the

surface markers on these cells were not characterized.
Allogeneic lymphocyte cytotoxicity, the rapid destruction of i.v.
injected allogeneic lymphocytes upon entering the host's lymphoid
tissue, may be another nonadaptive immune response in which NK
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cells play a role (16).

Fossum and Rolstad reported that

pretreatment with anti-NK cell antibodies (anti-asialo GMf and MRC
OX-8) profoundly reduced the proportion of allogeneic cells
phagocytozed by interdigitating cells (IDC).

Additionally, the rate of

killing of allogeneic lymphocytes differed substantially between
cervical and axillary lymph nodes and this difference correlated with
the densities of anti-asialo GMi+ cells in these nodes.

In vitro

studies with cell suspensions rich in IDC from peripheral lymph, but
poor in NK activity, could not demonstrate allogeneic lymphocyte
cytotoxicity (16).
There is more than one mechanism by which NK cells
recognize and kill their target.

First, and most clearly understood, NK

cell killing can be directed by opsonization of target cells with
antibody.

These IgG molecules are bound to CD 16, the FcR receptor

for IgG, on the NK cell surface, triggering granule exocytosis and toxin
secretion.

NK cells are the principal mediator of this form of

cytolysis, known as antibody-dependent cell-mediated cytotoxicity
(ADCC) (1).

The interaction with the FcR of NK cells may also evoke

pleiotropic effects under permissive conditions, and is not restricted
solely to the function of ADCC (17).

NK cells can also lyse susceptible

targets spontaneously by a second mechanism, which, although
poorly understood, has generally been thought to occur without
specificity and without MHC.

Anti-IgG or anti-CD 16 FcR antibodies

which inhibit ADCC do not prevent NK killing (6), indicating that in
this type of killing, target recognition is not mediated via the Fc
receptor that functions in ADCC killing (18).
With the exception of the CD 16 FcR used in ADCC, there is no
definitive information yet on any type of receptor used by NK cells
for target cell recognition and killing (6).

Despite the fact that NK

cells have a limited target cell range, no specific NK-associated
surface receptor or target ligand has yet been defined (19).
Although a molecular structure recognized by NK cells has not been
defined, there is evidence that NK cells are capable of killing with
specificity in a non-ADCC, non-MHC restricted manner.
The existence of NK specificity has been most simply
demonstrated by the phenomenon of "cold target inhibition".

In this
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experimental situation one NK target cell type (unlabeled) can inhibit
lysis of a different NK target type (labeled) by competing for effector
cells (1), Cells that are not NK targets do not compete. Ciccone et at
first reported specific lysis of allogeneic cells by CD3‘, CD2+, CD56+
lymphocytes after their activation in a mixed lymphocyte culture in
the presence of exogenous IL-2 (20).

After a ten day coculture, these

cells displayed cytolytic activity against PHA-induced blast cells
bearing the stimulating alloantigens but not against autologous or
unrelated allogeneic blast cells (20).

Coculture with an autologous

stimulator, or without IL-2, did not result in cytolytic activity
directed at autologous or allogeneic cells, although cytolytic activity
against K562 erythroleukemia cells (a classical NK target) was
preserved in these controls.

From these MLC-stimulated CD3" cells,

clones were derived that lysed allogeneic lymphoid cells with
apparent specificity, although the expression of CD 16 and CD56 on
these clones was not reported (19).
CD3", TCR-, CD 16+ and/or CD56+ NK lines and clones with
apparent antigen specificity have been described (19).

In addition to

displaying potent cytolytic activity against K562 cells, these clones
lysed their specific stimulator lymphoblastoid cell line (LCL) to a
significantly to a greater extent than irrelevant LCL.

This selective

killing was inhibited by the addition of cold simulator LCL or K562
cells, or anti-LFA-1 mAbs, but not by irrelevant LCL or mAbs to CD3,
class I or II MHC antigens (19).
The presence of a novel "antigen receptor" that may recognize a
set of polymorphic endothelial cell antigens distinct from human
leukocyte antigens was suggested by a study by Bender et al. They
used cytotoxicity assays to demonstrate the ability of NK cells to lyse
preferentially the line of microvascular endothelial cells to which
they were previously bound for only 90-min (21).

CD3", CD16+

lymphocytes preferentially killed endothelial cells (ECs) with which
they were cocultured over endothelial cells of unrelated donors (21).
Antibodies blocking CD3, CD4, CD8, class I and II did not block killing,
whereas anti-LFA-1 antibody consistently inhibited cytotoxicity,
likely because of its role in leukocyte binding to ECs (21). Their
results suggest that cytotoxic NK lines bind to their stimulating ECs

7

via both nonspecific and specific ligand interactions, and further
suggest that the basis for their specific cytotoxicity may lie, at least
in part, with specific binding (21).
As the membrane target structures have not been identified, it
is not known whether different NK cells react with the same or with
different target antigens (7).

In fact, many studies have indicated

that NK cells are not a homogeneous population in regard to
expression of surface markers and cytotoxicity (22) but rather that
subsets of NK cells recognize one or a limited number of target cells.
Allavena and Ortaldo studied the heterogeneity among many clones
of human NK cells with regard to phenotype and their patterns of
cytotoxic reactivity towards a variety of tumor target cells (22).

To

determine whether the tumor specificity and surface antigenic
profiles of NK cells are clonally distributed or whether individual
clones of NK cells display the heterogeneity associated with the
entire NK cell population, they tested the cytotoxicity of 196 clones of
cultured LGL from three donors against a panel of tumor target cell
lines, and found that the receptors recognized on NK-susceptible
targets are clonally distributed among the LGL population.
Interestingly, they also found that although most clones
demonstrated both NK and ADCC killing, some other clones, which
had NK activity, did not have ADCC, or vice versa.

However, the cell

surface phenotype of many of the LGL-derived clones included T cell
markers, and the heterogeneity may represent different cell
populations and not subsets of a single NK cell population.
NK cells isolated from individuals exhibit different
allospecificities expressed by normal allogeneic target cells (23).
Allavena and Ortaldo used their data from clones derived from
purified preparations of LGL to support the hypothesis that the
heterogeneity of the entire NK population is attributable to a mixture
of clones that vary substantially in their target specificities and
phenotypes (22).

Regardless, while antigen-specific receptors have

not been defined, and the molecular basis for such activity unknown,
these studies indicate that NK cells do kill allogeneic cells selectively.
Furthermore, this ability appears to be clonally distributed.

In

addition, the experimental data hint at the possibility of an NK cell
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repertoire for the recognition of allogeneic cells, albeit a limited one
in comparison to the T or B cell repertoire.
Now that it has been established that at least a subset of NK
cells recognize allogeneic cells, the question posed is how is this
specificity is achieved?

Some research indicates that specific NK

killing is MHC restricted.

An inverse relationship between the

expression of class I MHC antigens on target cells and sensitivity to
NK reactions has been reported by several groups (3).

Dawson et al.

described studies in which infection of NK sensitive cells by strains of
adenovirus known to decrease MHC class I molecule expression
greatly enhances cytotoxicity (3).

In general, target cell MHC class I

antigen expression correlates with resistance to NK cell-mediated
lysis (24).

Thus, the potential role of MHC gene products as signal

structures altering recognition by NK cells remains controversial (3).
Two models originally proposed to explain recognition of MHC
class I deficient cells in murine hybrid resistance are applicable to
the human alloreactive NK cell clones discussed above (25).
called 'effector inhibition' and “target interference?

In the

They are
effector

inhibition' model, NK cell-surface molecules engage MHC class I
antigens which consequently deliver inhibitory signals, requiring NK
cell receptors that distinguish between different MHC class I alleles.
In target interference, the NK cell receptors for specific antigens
would not bind to target structures as they are masked by
autologous MHC class I alleles.

'Target interference’ requires that NK

cell receptors recognize different non-MHC target structures, and that
MHC class I alleles can distinguish and interact with different target
structures.
Supporting the

effector inhibition' model is the hybrid

resistance phenomenon, the MHC-linked, NK cell mediated rejection
of homozygous parental bone marrow grafts by heterozygous Fj
irradiated mice. Studying scid/scid mice challenged with H-2
homozygous bone marrow cells that are either Hh-1+ or Hh-1",
Murphy et al. presented evidence that these noncodommantly
inherited histocompatibility determinants may be specifically
recognized by NK cells, leading to graft rejection (3).
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These models are not mutually exclusive and the 'masked'
nonself determinant in the target interference model might be a
polymorphic, MHC-encoded Hh antigen (25).

In both models, a

somatic, MHC-controlled determination of the NK cell receptor
repertoire would be necessary for self-tolerance.

This is supported

by studies on human alloreactive NK cell clones, and by studies of
hybrid resistance, H-2 transgenic and beta2-m knockout mice (25).
The studies on human alloreactive NK clones, as well as mouse
hybrid resistance and transgenic studies, stress the non¬
responsiveness to self and the reactivity to qualitatively MHCmismatched targets (25).

Studies of transgenic mice provided

evidence that MHC class I genes regulate the NK repertoire of
transplant recipients as well as the NK susceptibility of grafted cells
(25).

Bone marrow cells from gene "knockout" mice indicate that loss

of MHC class I expression leads to NK sensitivity (25).
Karlhofer et al. reported that NK cells with a surface molecule
(LY-49) that specifically interacts with the peptide-binding domains
of the MHC class I alloantigen do not lyse cells with the MHC domain,
despite efficient spontaneous lysis by Ly-49‘ effector cells (24).

In

order to characterize NK cell-mediated specificity, Ciccone et al.
studied the target cells to determine that susceptibility to lysis is
inherited in an autosomal recessive fashion (26).

They found that

lysis of normal allogeneic cells by NK cells can be clearly
distinguished from conventional non-MHC restricted lysis of tumor
cells (26).

While cloned NK cells specifically lysed appropriate

normal allogeneic cells, the lysis of tumor target cells was clearly
unrelated to this phenomenon (26).
Even so, most research supports that hypothesis that specific
NK killing is non-MHC restricted.

Regarding antigens seen by NK

cells, it is agreed that the expression of either class I or class II MHC
gene products on target cells is not required for the development of
cytotoxicity.

Suzuki et al. showed that antibodies to HLA class I, or

HLA-DR had no effect on the lysis of target by either NK killing (of
K562) or specific NK killing (of stimulator lymphoblastoid cell line)
(19).

What then, could be the nature of the structures expressed on
non-MHC restricted NK cells conferring upon those cells the capacity
to recognize their targets?

Little is known about the molecules

involved in non-MHC-restricted killing.
postulated.

Several theories have been

First, non-MHC-restricted killing may be mediated by

multiple cell interaction/adhesion molecules present on the cell
surface interacting with their natural ligands on the target cell.
Selectivity of NK cells might be determined by the relative
expression of several cell surface molecules and receptors, with no
single molecule playing a unique and essential role (6).

Such

molecules include CD11/CD18, CD2, and CD45 present on NK cells.
Sufficient engagement of one or more of these molecules could result
in NK cell activation and target cell death (27).
The surface molecules of the CD! 1/CD 18 family appear to play
important functional roles in NK cell killing.

Patients with selective

deficiency of either are deficient in NK cell activity, which is
probably a consequence of inability to bind target (6).

CD56 may

play an accessory role as a mediator of nonspecific adhesion between
allospecific NK effectors and their targets.

However, given the

existence of multiple isoforms, the variable expression of these
isoforms on allospecific NK lines, and the failure of any of anti-CD56
mAbs to affect the lysis by NK cells of "nonspecific" targets, such as
K562, the likelihood that CD56 plays an accessory role as a mediator
of nonspecific adhesion is poor (2).
Laminin, which increases on the NK cell surface upon
stimulation with IL-2, may act in prolonging lysis (6).

Schwarz and

Hiserodt demontrated that IL-2 activated NK cells which generate
broadly reactive non-MHC restricted cytotoxicity express laminin¬
like molecules on their surface while cells not expressing these
activities do not appear to express such structures (28).
Furthermore, anti-laminin antibodies block cytotoxicity at a
postbinding stage, without inhibiting NK-target cell interaction (6).
Another theory is that non-MHC restricted specificity may be
conferred by NK cell-specific 'Teceptor(s)" that interact with specific
moieties expressed on NK-sensitive target cells.

Non-MHC-restricted

killing of K562 leukemia cells by CTLs could be inhibited by

antibodies to CD3/TCR, suggesting that these cells may recognize
target via the CD3/TCR receptor (5).

Although an NK target

recognition structure has not been identified, several molecules have
been described that are NK cell-specific and appear to modulate NK
cell-mediated killing, including two on human NK cells (27).
Moretta et al. identified functional surface molecules which are
expressed variably within NK cell clones and presence of one
combination of these markers correlated with NK cell ability to
mediate specific lysis of normal allogeneic cells (29).

This study

implicated the involvement of one molecule, EB6, in specific NK cell
recognition.

However, other NK clones possessing the EB6 molecule

did not lyse the specific target, further complicating the
interpretation of the molecule's significance.
Moretta et al. also described GL183, a cell surface molecule
present on a phenotypically stable subset of NK cells whose cytolytic
behavior is modulated by anti-GL183 mAb (9).

However, GL183

probably acts more as an regulator of function and is less likely to be
involved in alloantigen-specific recognition as it is invariant in
structure (2) and is not associated exclusively with NK activity (18).
CD2 and CD 16, which have been shown to mediate signal
transduction and activation of cytoxic mechanisms, are unlikely
candidates for the same reasons (2) and that mAbs directed against
them fail to inhibit recognition and lysis of NK-susceptible target
cells (30).
Monoclonal antibodies specific for CD45 have been reported to
inhibit NK cell lysis of selected tumor cells, suggesting a possible role
in conferring NK specificity, however CD45 is not NK cell-specific, as
it is expressed on the majority of hematopoietic cells (30).
CD56, of which at least four distinct isoforms have been found,
exist variably on allospecific NK lines (2).

Two mAbs, which by

immunoprecipitation analysis revealed they recognized distinct
molecular isoforms of CD56, were generated that bound selectively to
the majority of CD3", CD16+, CD56+ lymphocytes.

They inhibited the

lysis of specific allogeneic target cells by a panel of alloreaetive NK
lines, without affecting the ability of these cells to kill the classical
NK target K562 (2).

The role of CD56 in NK killing is incompletely

understood, however, the finding of multiple CD56 isoforms on NK
cells is consistent with the hypothesis that these isoforms constitute
an allorecognition apparatus with limited heterogeneity.

In studies

by Nitta et aL, however, the contribution of CD56 to NK cell
cytotoxicity and binding could be demonstrated only when the target
cells also express CD56 (31).

This would limit the target cell

population of CD56 mediated toxicity to neural and muscle cells,
which contain the N-CAM isoform, and other CD56 containing tissues.
In the current study, I attempted to further characterize
membrane antigens on the surface of NK cells which are involved in
alloantigen target recognition.

Previously this lab created NK cell

lines and clones against RPMI8866, an immortalized B cell line, which
preferentially lysed the stimulating B cell line and were minimally
cytotoxic for a third party of autologous B cell targets (Bender,
unpublished data).

A monoclonal antibody called C8, also created in

this lab, was specific for a surface molecule on RPMI8866 and, when
incubated in cytotoxicity assays, blocked killing of the RPMI8866
target cell but not of K562.

In fact, there were CDS', CD3", CD16+,

CD56+ RPMI8866-stimulated NK clones whose lysis of RPMI8866
cells was 100% inhibited by monoclonal C8.

From these data, it was

concluded that RPMI8866 cells are specifically recognizable NK
targets, and that the molecule recognized by C8 is a target ligand on
the B cell which binds to a putative NK receptor.
My project was directed at proving the hypothesis that the NK
cells generated by stimulation with these B cells do have a receptor
structure that enables them to recognize and specifically lyse these
targets.

Murine monoclonal antibodies specific for CD3", CDS', CDS'

NK cells were generated and screened for specificity to the activated
NK cell and effect on NK cell behavior in cytotoxicity assays.
Antibody binding was measured on fresh NK cells versus NK cells
activated by co-culture with RPMI8866.

Cytotoxicity assays

compared the effect of antibody on NK killing of the specific target,
RPMI8866 B cells, with general cytotoxicity of K562.

The results

support the hypothesis that NK cells have surface molecules which do
confer specificity and, when blocked by antibody, inhibit alloantigen
target recognition.

METHODS
Isolation of CDS', CDS', CD8~, CD16+, CD56+ Lymphocytes.

Peripheral

blood mononuclear cells were isolated by Ficoll-Hypaque (Sigma, St.
Louis, MO) gradient centrifugation and were monocyte and B cell
depleted by plastic adherence followed by passage over nylon wool
columns.

To obtain CD3", CD5', CD8" cells, cells devoid of monocytes

and B cells were incubated with anti-CD3 (7D6) mAb for 20 min. at
4°C, washed twice, and applied to plastic petri dishes (BectonDickenson #1005) (which were precoated for at least twenty min.
with 10 pg/ml goat anti-mouse IgG in Tris-HCl, pH 9.5, and washed
with PBS) for 70 min. at 4<>C. (panning).

Nonadherent cells were

retrieved by gently washing the plates with cold PBS 1% FBS.

They

were then incubated with anti-CD5 (SI.6) mAb and panned on anti¬
mouse IgG to remove any residual CD5+ cells.

Nonadherent cells

were retrieved and incubated with anti-CD8 (3B5) mAb and panned
on anti-mouse IgG to remove any residual CD8+ cells.

The resultant

lymphocyte population contained >90% CD56+ and <1% CD3+ cells by
flow cytofluorometric analysis.
Production of 1F7 and 1F8 mAbs.

A 6-wk-old female BALB/c mouse

was immunized with CD3-, CD5-, CD8-, CD16+, CD56+ NK cells.
Immunizations were performed using Ribi adjuvant (Ribi
Immunochem Research, Inc., Hamilton, MT) according to the
manufacturer's protocol.

The immunization schedule consisted of 3

intraperitoneal injections of 10^ of the relevant cells in 0.5 ml. PBS.
After the third immunization, the mouse was sacrificed humanely by
cervical dislocation and splenectomized.

The sensitized splenocytes

were fused with SP2/0 murine myeloma cells (non-Ig producer),
thus creating hybrid cells which produce antibodies directed against
the immunizing NK cells.

The hybridomas were placed in a limiting

dilution, and 1 cell/well was placed in 96-well round-bottom plates
(Becton-Dickinson, Lincoln Park, NJ).
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Culture

medium.

Standard culture medium consisted of RPMI 1640

(Biofluids, Inc., Rockville, MD or Gibco, Grand Island, NY)
supplemented with

10% heat-inactivated fetal bovine serum

(Biofluids), 1% (2mM) L-glutamine, and 1% streptomycin (100 pg/
ml)/penicillin (100 U/ml).

Medium for NK cell cocultures included

0,1% 2-Methionine (2-ME).
(standard plus

Hybridomas were in HAT medium

1% hypoxanthine-thymidine, 0.1% aminopterin) for

first 2 weeks before being switched to HT (without aminopterin) and
then standard.

Hybridomas were grown in standard culture medium

and split every 2 to 3 days.
RPMI8866

Coculture.

Peripheral blood lymphocytes were isolated on

Ficoll-Hypaque gradients, and spun once at each 2000, 900, and 700
rpms for 5, 10, and 15 min., respectively.

The fast spin removed

residual Ficoll, and the two slow spins removed platelets.

Cells were

brought up to a volume of 10^ cells/ml in standard medium plus 2ME.

1 ml was placed in wells of 24-well flat-bottomed multi-well

plates (Becton-Dickinson, Lincoln Park, NJ).

RPMI8866 stimulator

cells at 4 x 10^ cells/ml were Cs-irradiated at 6000 rads., and 0.5 ml
was placed into each well.

Cocultures were refed on days 7 and 10,

and harvested on day 14, with about 70% CD3', CD16+, CD56+ cells by
flow cytofluorometric analysis.

Thereafter, the cocultures could be

prolonged either in their wells or in bulk by refeeding with
irradiated RPMI8866 stimulator cells at a ratio of 2 x 10^

feeders:

106 NK cells on a weekly basis.
Screening

of Hybridoma Supernatants.

166 hybridoma supernatants

were screened on the basis of their ability to bind to activated CD3",
CD5", CD8‘, CD16+, CD56+ lymphocytes by flow cytofluormetric
analysis.

123 hybridoma supernatants were also screened for

staining on RPMI8866 B cells and 99 were tested for antibody
binding to CD3+ T lymphocytes.

19 predominantly NK cell specific

antibody secreting hybridomas were then evaluated in cytotoxicity
assays with RPMI8866 targets.

Of these, 2 antibodies were also

tested in cytotoxicity assays with K562 as targets.

When screening

the hybridomas for antibody recognizing NK cells, the negative

control antibodies used were HPCG14 (murine irrelevant IgGl) and
OKT3 (anti-CD3), and the positive control antibodies were W6/32
(anti-HLA class I) and 3G8 (anti-CD 16).

When screening the

hybridomas for antibody recognizing B cells, the negative control
antibody used was HPCG14 and the positive control was C8 (antiRPMI8866 cells).

When screening the hybridomas for antibody

recognizing T cells, the negative control antibody used was 3G8 and
the positive control antibodies were OKT3 and 7D6 (anti-CD3).
One and Two-color Flow Cytofluorometric Analysis.

For surface

marker analysis, 2 x 10^ cells were stained with the saturating
amounts of appropriate mAb, and if unconjugated, washed and
stained with fluoresceinated goat anti-mouse IgG+IgA+IgM(H+L)
Double Staining Grade (Zymed).

Each incubation was for 25 min. on

ice to prevent cell-surface modulation of Ag.

All samples were

placed in 0.35 ml of staining buffer (PBS 1% BSA 0.1% sodium azide).
Events were collected on a flow cytometer (FACSort, BectonDickinson, Mountain View, CA), gated to exclude nonviable cells, and
analyzed with FACScan Research Software (LYSYS II, BectonDickinson).

Results are expressed as arbitrary normalized

fluorescence histograms, i.e., number of cells vs. fluorescence
intensity.
For two color staining, cells were stained with a FITCconjugated antibody for 10 min. and then a PE-conjugated antibody
for 15 additional min. before the cells were washed and placed in
staining buffer.

Controls for phenotyping the cells included cells

stained with an irrelevant antibody bound to FITC and to PE.
The mAbs used in these and other studies were anti-Leu-4FITC (anti-CD3, AMAC, Inc.), anti-Leu 11-FITC (anti-CD 16, AMAC,
Inc.), anti-CD56-PE (AMAC, Inc.), Irrel-FITC (Sigma), Irrel~PE
(Sigma), HPCG14 (murine irrelevant IgGl), OKT3 and 7D6 (anti-CD3),
SI.6 (anti-CD5), 3B5 (anti-CD8), W6/32 (anti-class I), 3G8 (antiCD16), TS1.22 (anti-CDlla, anti-alpha subunit of LFA-1), C8 (antiRPMI8866), anti-CD56.
In order to determine whether mAbs 1F7 or 1F8 block binding
of anti-CD56 antibody,

CD3", CD16+, CD56+ lymphocytes were treated

with 1F7 or 1F8 or anti-CD56 or 3G8 mAbs at 4°C for 30 min.,
washed and then stained with irrelevant PE second step to assess
background blocking which was zero.

The two test mAbs and anti-

CD56 were incubated on separate NK cells, washed and stained with
anti-CD56-conjugated PE second step and analyzed as above.
(FITC=fluorescein isothiocyanate conjugated, PE=phycoerythrinconjugated)
Supernatant

Concentration.

Selected supernatants were concentrated

to 25x with Centriprep-30 Concentrators (Amicon, Inc., Beverly, MA).
After prerinsing concentrator with deionized water, supernatant was
placed in concentrator and centrifuged at 2800 rpm for 15 min.
Filtered supernatant was removed and the concentrator was re-spun
twice at 2800 rpm for 5 min. each.

Retentate was removed with

syringe and syringe-filtered into aliquots for storage.
Isotyping and Enzyme-Linked Immunosorbent Assay.

Plastic ELISA

plates were precoated with 1 pg/ml each of goat anti-mouse IgG and
IgM in a coating buffer and incubated overnight at 4°C.

Plates were

washed twice with PBS 1% BSA 0.1% sodium azide and incubated
overnight with PBS 3% BSA 0.1% sodium azide filling the wells.
Plates were washed three times with .05%Tween-20.

Test

supernatants were added and incubated at 4°C 2 hours-overnight.
Plates were washed three times with .05%Tween-20„

Goat anti¬

mouse conjugated alkaline phosphatase second step was added and
the plate incubated at least 2 hours at room temp.

Plates were

washed three times with .05%Tween-20 and twice with PBS 1% BSA
0.1% sodium azide.

Disodium p-nitrophenyl phosphate (Sigma)

substrate solution was added.

Plates were read at 15 min. intervals

by an ELISA-plate reader (Dynatech).
Isotyping of selected antibodies was done using an ELISAbased isotyping kit (Southern Biotechnology Assoc., Birmingham, AL).
Cytotoxicity assay.

The most commonly used test of NK cell activity

in vitro (assay for NK cell cytotoxicity) is the 51(> (sodium
chromate)-release cytotoxicity assay, in which NK cell-containing cell

preparations are mixed with a constant number of 51

Cr-labeled

K562 or other target cells at one or more effector-to-target cell
ratios, and cell lysis is evaluated, after 3-4 hours of incubation at
37°C, by measuring the amount of ^Iq- released in the supernatant
fluid (32).
Cytotoxicity of NK cells against RPMI8866 cells and K562 cells
was measured in a 4 h 51cr-release microcytoxicity assay using 96well U-bottomed microplates (Becton Dickinson, Lincoln Park, NJ).
The target cells were labeled with 75 pCi of Na2*^Cr04 per 1.5 x 10^
cells, washed, and seeded into 96-well culture dishes at 5 x 10^
cells/well in suspension.

Test and irrelevant isotype-matched

control antibodies at the same approximate concentrations were
placed in appropriate wells in order to explore the role of cell surface
molecules in cytotoxicity.

Suspensions of effector cells were added to

quadruplicate wells to give various E/T ratios, ranging from 100:1 to
0.5:1, in a final volume of 200 jul.

After an incubation at 37°C for 4 h,

150 pi of supernatant was removed from each well and counted in a
gamma counter to determine experimental release (ER).

Spontaneous

release (SR) was obtained from wells receiving target cells and
medium only, and maximum release (MR) was obtained from wells
receiving 1% Triton X-100.

The percent cytotoxicity was calculated

by the following formula:
cytotoxicity = (ER)-(SR) x 100
(MR)-(SR)
SR was 20% of max when RPMI8866 cells were used as a target.

SR

was 7.5% of max when K562 cells were used as a target.
Experimental replicates consistently varied by <10%.
All work was performed by the author.

Dr. Bender taught all

experimental protocols and use of equipment, as well as assisting in
early cytotoxicity assays and the running of FACSort samples in large
experiments.

Jean Wilson and Leslie Tacket instructed me on tissue

culture technique and preparation of reagents.

RESULTS
Activation and proliferation of NK cells.

Cell populations enriched in

activated CD16+, CD56+ lymphocytes were obtained by coculture of
PBLs with RPMI8866 cells for 2 wk.

As shown in Figure 1A for a

representative coculture, the resulting lymphocyte population was
70% NK cells and 30% T cells by flow cytometry.

Purification of CD3",

CD8"’ CD16+, CD56+ NK cells was achieved by panning for removal of
CD3+ T cells as described in Methods.

Figure IB shows a phenotype

representative of the nonadherent cells from a panning after
incubation with mAb 7D6 (anti-CD3),
<0.5% CD3+ T cells.

>99% CD16+, CD56+ NK and

Cells purified in this way were used in

experiments requiring pure NK cell populations.

A

.

Figure 1

Two-color flow cytometric analysis of stimulated

lymphocyte phenotype (A) after coculture of PBLs with RPMI8866
cells; (B) of nonadherent coculture cells following panning with antiCD3 mAb.

FL1, recorded in log scale on the x-axis, indicates the

intensity of FITC staining.

FL2, recorded in log scale on the y-axis,

indicates the intensity of PE staining.

Evaluation of NK Cytotoxicity.

To determine whether these CD3“,

CD16+, CD56+ NK cells had cytolytic activity, they were tested as
effectors in 4 h ^lcr-release assays against the original stimulator
lymphoblastoid cell line, RPMI8866 as well as NK sensitive K562
cells.

As shown in Figure 2, these cells exhibited potent lysis of both

RPMI8866 and K562 cells which titers with the E : T ratio.

Effector: Target Ratio

Figure 2.

Cytotoxic activity of RPMI8866-stimulated CD3", CD16+,

CD56+ NK cells was tested against the original stimulator RPMI8866
cells and K562 cells.
Expression of molecules on activated NK cells generated from
peripheral blood.

Among the 166 hybridoma supernatants tested

against activated CD3", CD8", CD16+, CD56+ lymphocytes and analyzed
by flow cytometry, 54 had antibody that bound to the NK cells.

Of

those antibodies, 37 also bound to molecules on the surface of B cells,
and 19 also bound to molecules on the surface of activated CD3+ T
cells.

Of the 54 NK-positive antibody secreting hybridomas, 1

produced antibody specific for NK cells with no staining of B or T
cells (Figure 3), 3 which were negative on B cells but were slightly
positive on T cells (Figure 4), 2 which were negative on B cells but
very positive on T cells (Figure 5), 1 which was slightly positive on B
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cells but negative on T cells (Figure 6), 3 which were slightly positive
on both B and T cells (Figure 7), and 2 which were slightly positive
on B and very positive on T cells (Figure 8).

The rest were moderate

to very positive on B cells, T cells, or both (data not shown).
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Staining of mAb 3B8 on NK, B, and T cells.

mAb 3B8

recognizes a surface molecule unique to NK cells.
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This staining is

representative of the three mAbs which recognize molecules which
are present on NK cells and slightly on T cells, but absent on B cells.

NK
3»-“1
1

4B9

d
%

TJ

B
i

4B9

|

d !
#
i ...

u-o 'I

,*j !
i

..
—0
-010015Q20SE5&
?SC -,

Figure 5.

T

>•-

id
•io...
i
—g

-01001

“SC ->

-SC --

Staining of mAb 4B9 on NK, B, and T cells, which is

representative of the two mAbs which recognize molecules on NK
and T cells, and not on B cells.
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The molecule

recognized by mAb 3F6 is present on NK cells and a subset of B cells.
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Staining of mAb 3E6 on NK, B, and T cells, which is

representative of the mAbs which recognize a surface molecule on all
three cell types.

NK
3D 5

—*
uloD ..I.—
'
33 1001S3200S=a

~ 3C — >

Figure 8.

T

B

J21
! ^>4
1

a. o ;

3D5

n

‘3 30l0015eS0025a.

j_jd

.001502002^

r SC --

Staining of mAb 3D5 on NK, B, and T cells, which is

representative of the two mAbs which recognize a surface molecule
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density on B cells.
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Staining of mAbs A) 1F7 and B) 1F8, which, from data

obtained by following experiments, were found to be of interest.
Initially, it was concluded that mAb 1F7 recognized a surface
molecule on NK, B, and T cells.

However, it was later determined that

mAb 1F7 was of IgM isotype (data to follow).

This makes its staining

pattern somewhat difficult to interpret, because an irrelevent
antibody of IgM isotype was not used in the early screening
experiments.

Thus, the small amount of reactivity with B and T cells

may be a consequence of nonspecific binding.
evaluation.

This requires further

Monoclonal 1F8 recognizes a surface molecule which is

on NK cells and less on T cells, but not on B cells.
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Figure 10A, B, and C shows the controls for the staining of
CD3-, CD8", CD16+, CD56+ NK cells, RPMI8866 B cells, and CD3+, CD16'
T cells, respectively as described in Methods.

A
0KT3

i HPCC14

3B5 i
i

3G3

NK

B

C

Figure 10.

One-color flow cytometric analysis of cell surface

antigens on three cell types.

Positive and negative controls used for

staining (A) NK cells; (B) B cells; and (C) T cells.

In experiments

using CD3", CD8~, CD16+, CD56+ NK cells obtained as described in
Methods, HPCG14, OKT3, and 3B5 were negative controls, while 3G8
was the positive control.

For RPMI8866 B cells, HPCG14 was

negative, while C8 was positive.

For CD3+, CD 16' T cells, 3G8 was

negative, while OKT3 and 7D6 were positive.

Isotyping of mAbs.

Using an ELISA-based isotyping kit, mAh 1F7

and 1F9 were determined to be IgM, while mAbs 1E8, 1F8, 2G7, 3B8,
and 3E6 were found to be of IgGl isotype.

The negative controls

were standard medium and PBS 1% BSA 0.1% sodium azide.
control for IgGl was mAb 3G8 (anti-CD 16).
was OKT3 (anti-CD3).

Positive

Positive control for IgG2a

Positive control for IgM isotype was mAb

1H12, an endothelial cell specific antibody.

The results are shown in

Table 1.
Table 1.

Isotype of mAbs

IgGl

IgG2

IgM

media

-0.006

-0.005

-0.006

1% BSA

-0.006

-0.005

-0.006

3G8

+0.083

-0.004

-0.003

OKT3

+0.004

+0.118

-0.005

1H12

-0.002

+0.032

+0.111

1E8

+0.090

-0.001

-0.001

1F7

+0.005

-0.001

+0.121

1F8

+0.069

-0.002

+0.001

1F9

+0.006

-0.002

+0.165

2G7

+0.160

+0.011

-0.004

3E6

+0.069

-0.002

+0.004

In experiments requiring isotype-specific controls for mAbs

1F7 and

1F8, mAbs 1H12 and 2G7 were used, respectively.
Functional role of molecules bound by mAb in cytotoxicity by
activated NK cells.

The functional involvement of molecules bound

by these mAbs was tested.

CD3', CD16+, CD56+ NK cells were tested

for cytotoxic activity against RPMI8866 cells in the presence and
absence of mAbs.

The results of these experiments are shown in

Figure 11, A and B.

Although cytotoxic activity was high against the

target tested, killing of the RPMI8866 target was inhibited in the
presence of mAbs 1F7 and 1F8 at the 100:1 and 33:1

E:T ratios.

mAb 1F7 blocked 14% of killing at the 100:1 ratio and 54% of killing

25
at the 33:1 ratio.

mAh 1F8 blocked 13% of killing at the 100:1 ratio

and 36% of killing at the 33:1 ratio.
No significant effects on RPMI8866 target cell killing were
noted when using the other antibodies also reactive with CD3",
CD16+, CD56+ NK effector cells (mAbs 3D7, 1F9, 4B9, 3F6, 3E6, 4D10,
3D5, 3E2) or in the presence of the isotype matched controls (shown
in figures).

Anti-LFA-1 antibody was used as a positve control which

blocks killing by interfering with target cell adhesion.

This screening

procedure led to the identification of two hybridomas which secrete
antibodies (mAbs 1F7 and 1F8) which inhibit the cytolytic activity of
the NK cells against their original stimulator RPMI8866.

A

B
1F8
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Figure 11.

RPMI8866 + 1F7 mAb

RFMI8866+ 1F8 mAb

RPMI8866 + IgM mAb Control

RPMI8866 + IgGl mAb Control

RPMI8866 + anti-LFA-1 mAb

O-

RPMI8866 + anti-LFA-1 mAb

Partial inhibition of NK cell cytotoxicity of RPMI8866

stimulator cells by mAbs (A) 1F7 and (B) 1F8.
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Demonstration of Allogeneic target recognition.

In order to

determine whether these mAbs were blocking NK killing in general,
as opposed to allospecific killing, cytotoxicity assays were carried out
with both RPMI8866 cells and K562 cells as targets in the presence
of the mAbs and appropriate control mAbs.

Although significant

inhibition was achieved against killing of the RPMI8866 target as
shown in Figure 11, the same antibodies at the same concentration
did not significantly block killing of K562 at any of the effector :
target ratios (Figure 12, A and B).

This led to the identification of

two hybridomas which secrete antibodies (mAbs 1F7 and 1F8) which
inhibit the cytolytic activity of the NK cells against their original
stimulator RPMI8866 but not of K562.

That is, there appears to be a

specificity to the antibody inhibitory effects.

A

B
1F7

1F8

Effector: Target Ratio

■O—

Figure 12.

K562 + 1F7 mAb

K562 + 1F8 mAb

K562 + IgM mAb Control

K562 + IgGl mAb Control

K562 + anfl-LFA-1 mAb

—O—-

K562 + anti-LFA-1 mAb

No effect on NK cytotoxicity of classical NK target K562

by mAbs (A) 1F7 and (B) 1F8.
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Are mAbs 1F7 and 1F8 recognizing CD56?

Once functional

significance was established for the surface molecules recognized by
mAbs 1F7 and 1F8, more information regarding what they may be
was desired.

A flow cytometric experiment was completed in an

attempt to rule out the possibility that mAbs 1F7 and 1F8 are
recognizing isoforms of CD56, as anti-CD56 mAbs have failed to affect
the lysis by NK cells of "nonspecific" targets, such as K562, while
inhibiting the lysis of specific allogeneic target cells by a panel of
alloreactive NK lines (2).
In this experiment, mAbs 1F7 and 1F8, if not recognizing CD56,
should have no effect on the staining of anti-CD56 PE or irrelevant
PE.

As a positive control, CD56 should block the staining of anti-CD56

PE without blocking irrelevant PE.

As seen in Figure 13, anti-CD56

did not block the binding of anti-CD56 PE.
this.

Three possibilities explain

First, the titer of the anti-CD56 was not known, and the amount

used may have been too low to saturate cell surface molecules.
Second, as previously discussed, there are multiple isoforms of CD56.
These mAbs came from different hybridomas and may be
recognizing different isoforms.

Third, within isoforms, there are

multiple non-crossblocking epitopes that these different mAbs could
be recognizing.
Monoclonal antibody 1F8 did not affect the binding of antiCD56 PE.

Monoclonal antibody 1F7, however, appears to have

decreased the binding of anti-CD56 PE, lowering its mean
fluorescence from >100 to <50.

This may be due to nonspecific

blocking of the anti-CD56 PE, and may be a result of the bulky
pentameric structure of the 1F7 IgM antibody.

Since CD56 is present

only on NK cells and a minor subset of cytotoxic T cells, it is unlikely
that mAb 1F8 recognizes CD56 on these cells as the molecule it
recognizes are present at low densities on T cells (Figure 5).
Furthermore, neither the RPMI8866 or K562 target cells express
CD56, a requisite if CD56 mediated cytotoxicity is assumed to be the
cause, according to the previously mentioned studies by Nitta et al.
(32).

This requirement, however, is disputed by Suzuki et al. (2).
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Figure 13.

Monoclonal antibody blocking experiment.

NK cells

were treated with mAbs 1F7, 1F8, or CD56, before treatment with, in
one sample, irrelevent PE and, in another sample, CD56 PE.
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DISCUSSION
NK lymphocytes have the ability to lyse target cells without
apparent prior sensitization or MHC gene restriction (1-4).

Despite

the fact that NK cells have a limited target cell range, no specific NKassociated surface receptor or target ligand has yet been defined.
Traditionally, it has been concluded that these cells, in contrast to T
or B cells, lack a highly refined antigen recognition system, and are
only nonspecific effectors.

However, scrutiny of NK cytotoxic activity

reveals heterogeneity of both NK recognition and target structrures
(33).

In addition, murine NK cells have been shown to mediate the

genetically restricted hybrid resistance to parental bone marrow
allografts (3), a phenomenon that appears directed at the products of
noncodominant hematopoietic histocompatibility genes.

More

recently, evidence has been provided that human NK cells are
capable of alloantigen recognition (19,20).

Therefore, on the basis of

these observations it would appear that, contrary to previous
opinion, at least a subset of NK cells have the ability to distinguish
target cells.
The identification of surface structures involved in target cell
recognition by NK cells has become an area of active investigation.
Candidate markers must display a distribution restricted to
functionally relevant effector cells, and antibodies directed against
such putative receptors must alter the cytotoxic activity of such cells
(3).

In the present study, using NK cells stimulated with the NK-

sensitive RPMI8866 B cell line as an immunogen, two mAbs (1F7 and
1F8) were generated which inhibit lysis of RPMI8866 cells by CD3-,
CD16+, CD56+ NK cells without affecting the ability of these cells to
kill the classical NK target cell K562.
Double fluorescence and FACS analysis showed that 1F7+ and
1F8+ cells were consistently included in the CD3", CD16+, CD56+ cell
populations.

1F7 mAb recognizes a surface molecule on these NK

cells, and only questionably on B or T cells.

The molecule recognized

by mAb 1F8 is on NK and a percentage of T cells, while absent on B
cells.

It is not known if the 1F8+ T cells detected in activated

cultures arise from expansion of a small number of positive cells
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present in the peripheral blood, and/or if the molecule(s) is induced
by activation of previously negative T cells.
What do these mAbs recognize, and are they truly novel?
Given that mAbs 1F7 and 1F8 inhibit target cell lysis, it is unlikely
that they recognize CD2 or CD 16, since both anti-CD2 and anti-CD 16
mAbs enhance NK-cell mediated killing (9,30).

Studies using mAb

against CD8, a surface structure shared by some NK cells and T cells,
have failed to alter the cytotoxic activity of NK cells or the activity of
these cells after activation by IL-2 (28).

Unlike the molecules

recognized by mAbs 1F7 and 1F8, CD2 is present on all T cells.
Additionally, the patterns of antibody staining by anti-CD 16 and
anti-CD8 differ from that of both anti-lF7 and anti-lF8 (Figures 9
and 10).

Monoclonal antibodies specific for CD45 have been reported

to inhibit NK cell lysis of selected tumor cells, however, as it is
expressed on virtually all hematopoietic cells except mature
erythrocytes and their immediate precursors (30), it is unlikely to be
recognized by mAbs 1F7 or 1F8.

Monoclonal antibodies 1F7 and 1F8

clearly do not recognize CD11/CD18 (LFA-1), because they do not
block killing of K562 and, again, are subset-restricted.
Immunofluorescence analysis of the NK cells could not refute
the possibility that the antigenic epitopes recognized by these two
mAbs are closely associated with, if not identical to CD56.

Although

mAb 1F8 does not block the staining pattern of anti-CD56 mAb, it is
possible that it recognizes a non cross-blocking epitope.
also be the case for mAb 1F7.

This may

It does affect the anti-CD56 mAb

staining, but it is unclear that this effect is specific and not the result
of non-specific blocking by a large IgM antibody.

Using an irrelevent

IgM antibody in this experiment would resolve this issue.

The

question of whether these mAbs recognize and block an epitope on
NK CD56 is interesting because of the controversy regarding the
function of CD56, and its significance with respect to the NK-target
cell interaction.
In the study by Nitta et ah, CD56 was reported to be involved
in cytotoxic activity and only homotypic adhesion between NK cells
and CD56+ malignant neural cells, because targets without CD56 were
not susceptible to lysis by NK cells (31).

In contrast, results obtained

by Suzuki et al. suggests that CD56, of which they have detected at
least four isoforms, is directly involved in NK cell lysis of alloantigenspecific targets (2). In their study, the lymphoblastoid cell line
targets lacked any detectable expression of CD56, indicating that the
CD56 isoforms on the NK cell effectors mediate a heterotypic rather
than a homotypic interaction between NK cells and their targets.
They used the finding of multiple CD56 isoforms on NK cells, the
variable expression of these isoforms on allospecific NK lines, and the
failure of any of their anti-CD56 mAbs to affect the lysis of NK cell of
“nonspecific” targets such as K562 cells, to conclude that the CD56
isoforms constitute an allorecognition apparatus.
There is considerable information still to be obtained regarding
these molecules.

Plans for the future include:

specificity for the stimulator cells.

1) Testing absolute

Cold target inhibition studies

could be done to confirm the specificity of the NK cells for the
RPMI8866 stimulators.

To prove that they truly block allospecific

killing would require that they be tested with NK cells against a
panel of target cells.

2) Phenotyping of additional cells for surface

antigens recognized by mAbs 1F7 and 1F8.

For example, staining

freshly isolated T cells would answer the question of whether the
1F8+ T cells detected in activated cultures arise from expansion of a
small number of positive cells present in the peripheral blood,
and/or if the molecule(s) is induced by activation of previously
negative T cells.

Generating NK clones and screening them for

recognition by these mAbs would provide more information
regarding heterogeneity of expression of the molecules they
recognize.

3) Evaluating the possible role of molecules recognized by

mAbs 1F7 and 1F8 in signal transduction.

This can be accomplished

by measuring Ca^+ fluxes resulting from mAb crosslinking.
Assessing the ability of NK cells to specifically lyse the hybridoma
cells that produce antibodies (mAbs 1F7 and 1F8) against a candidate
triggering molecule on the effector cells, known as reverse ADCC, can
also be used as a sensitive test for the ability of the molecule to
transduce signals into the cell. For example, cytotoxic T cells
specifically lyse anti-CD3 mAb-producing hybridomas, and human
NK cells lyse anti-CD 16 mAb-producing hybridomas (27) and anti-

CD56 mAb producing hybridomas (2).

4) Biochemistry.

Immuno-

precipitation and/or western blotting would be necessary to assess
the molecular mass and extent of giycosylation of the surface
antigens recognized by these mAbs.

In order to conclude with

certainty that mAbs 1F7 and 1F8 do or do not recognize CD56, their
target ligand(s) would need to be immunoprecipitated and further
characterized.

And ultimately, 5) expression cloning from an

RPMI8866-stimulated NK cell cDNA library, 6) sequencing, 7)
transfection of cDNA into cells lacking NK activity, and 8) abrogation
of expression of proposed cDNA in NK cells with antisense cDNA
vectors.
With this information in hand, it would be clarified whether
the molecules recognized by mAbs 1F7 and 1F8 play a primary
(receptor) or a secondary (accessory) role in antigen-specific killing.
One would predict, if a molecule is a receptor involved in recognition
and mediation of cell death by NK cells, that: 1) it would be present
only on those cells that mediate this function; 2) absence of the
molecule would be associated with lack of function; 3) the
engagement of the molecule by its antibody would modulate its
function; 4) affinity purified antibodies which block target killing
could do so without disrupting primary target cell adhesion; 5)
transfection of specific cytotoxic cells with the gene or cDNA of the
molecule would enable them to mediate non-MHC-restricted killing;
and 6) the ligand for the receptor would be expressed on appropriate
target cells (27,28).
At present it is only known that the molecules recognized by
mAbs 1F7 and 1F8 fulfills two of these criteria.

They are present

only on those cells that lyse NK-sensitive targets and this killing is
partially inhibited, when engaged by their respective antibodies.
Taken together, these data suggest that 1F7 and 1F8 surface
molecules may exert a role in the activation or regulation of the
cytolytic function of human NK cells.

The antigenic determinant

recognized by 1F7 or 1F8 mAb could represent a "receptor" molecule
uniquely expressed on NK cells.

Determining whether either

molecule is a true NK recognition receptor will require additional
confirmation either by expression cloning, sequencing, and
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transfection of a full-length cDNA into cells lacking NK activity or by
abrogation of expression of the proposed receptor in NK cell lines or
clones with antisense cDNA vectors.
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